Home/Posts/Press Release
3 08, 2021

RocketVax successfully raises CHF 7.2 million of seed funding

By |2021-08-03T15:35:10+01:003rd August, 2021|Press Release|

RocketVax has successfully secured CHF 7.2 million in its Seed A financing to fund the pre-clinical development of its Covid-19 vaccine. Renowned institutional and private investors have funded this financing round. RocketVax is now launching the Seed B financing to fund the first phase of clinical development in humans. RocketVax AG is pleased to announce [...]

6 07, 2021

Batavia Biosciences to develop innovative clinical process for RocketVax’s second generation COVID-19 vaccine

By |2021-07-06T14:18:30+01:006th July, 2021|Press Release|

Today, Batavia Biosciences announces their collaboration with RocketVax, a subsidiary of Swiss Rockets AG developing vaccines based on breakthrough genetic engineering. Under the agreement, Batavia will develop the clinical process and deliver clinical product of RocketVax’s vaccine candidate against the SARS-CoV-2 virus. RocketVax is developing a promising second generation COVID-19 vaccine candidate, called RVX-13 which, [...]

17 06, 2021

Basel government approves one million for research to develop novel vaccine against SARS-CoV-2 coronavirus

By |2021-06-18T09:22:13+01:0017th June, 2021|Press Release|

Basel University Hospital, the University of Basel and the Swiss Tropical and Public Health Institute have agreed to collaborate with the company RocketVax and jointly advance research to develop a novel vaccine against the SARS-CoV-2 coronavirus. The University Hospital Basel (USB), the University of Basel and the Swiss Tropical and Public Health Institute (Swiss TPH) [...]

3 06, 2021

RocketVax AG and Swiss Rockets AG expand science and leadership teams

By |2021-06-03T15:01:52+01:003rd June, 2021|Press Release|

RocketVax AG and Swiss Rockets AG have recruited additional experts to join their scientific and leadership teams to accelerate the development of the SARS-CoV-2 vaccine RVX-13 and to position the companies for the future. Swiss Rockets AG founded the subsidiary RocketVax AG in 2020 to develop a next-generation vaccine against SARS-CoV-2 (RVX-13). To accelerate the [...]

16 04, 2021

Innosuisse supports the Basel biotech company RocketVax in its research into the second generation of SARS-CoV-2 vaccines

By |2021-04-19T13:39:52+01:0016th April, 2021|Press Release|

When the ongoing coronavirus pandemic broke out at the start of 2020, Swiss Rockets AG set itself the challenge of manufacturing a vaccine that activates multiple lines of immune system defense to combat SARS-CoV-2 most effectively. To achieve this mission, it founded the Basel-based subsidiary RocketVax AG in the summer of 2020. To start working [...]

10 02, 2021

Prof. Dr. med. Alex A. Adjei, Chairman of the Oncology Advisory Committee of Swiss Rockets, is the 2020 Adi F. Gazdar IASLC Merit Award Recipient

By |2021-02-10T16:42:57+01:0010th February, 2021|Press Release|

Prof. Dr. Alex A. Adjei has been chosen as the inaugural recipient of the Adi F. Gazdar IASLC Merit Award. For his many accomplishments and a passion for cancer drug development, as well as for mentoring the next generation of specialists during his multifaceted career, Prof. Dr. Adjei has been selected for the award by [...]

10 11, 2020

Swiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine

By |2020-11-16T09:43:59+01:0010th November, 2020|Press Release|

The rapid development of an effective and safe vaccine against SARS-CoV-2 is a top priority for Swiss Rockets AG. A Basel-based subsidiary, RocketVax AG, was founded to utilize innovative Swiss technologies and expertise to achieve this goal. "The development of a SARS-CoV-2 vaccine might be more complex than anticipated, and the first generation of vaccines [...]

27 08, 2020

The biotech company Swiss Rockets AG enters into a strategic partnership with daura AG – the Swiss platform for digital stocks

By |2020-08-28T08:23:01+01:0027th August, 2020|Press Release|

The collaboration between Swiss Rockets and daura is designed to facilitate the financing of promising life science projects. With the daura platform, investments in biotech start-ups will be possible digitally even with smaller amounts and without transaction costs. By selecting research projects in oncology and immunology, the biotech company Swiss Rockets supports a paradigm shift, [...]

5 06, 2020

Swiss Rockets AG has assembled an Advisory Committee of renowned Oncology scientists to help it develop new cancer treatments

By |2020-06-09T08:28:22+01:005th June, 2020|Press Release|

Inspired by cancer patients and dedicated to their well-being, Swiss Rockets provides access to innovative anti-cancer treatments. Internationally recognized experts of the Oncology Advisory Committee accelerate and secure drug discovery programs as well as advise and lead clinical development of the most promising technologies.   Prof. Dr. med. Alex A. Adjei, Chairman of Oncology Advisory [...]

9 03, 2020

Swiss Rockets AG: Scientific and Drug Discovery Advisory Committee opens a new chapter in cancer drug discovery and development

By |2020-03-18T20:41:40+01:009th March, 2020|Press Release|

Swiss Rockets AG strives to provide cancer patients access to breakthrough innovative anti-cancer treatments. The highly experienced Scientific and Drug Discovery Advisory Committee of Swiss Rockets will provide expertise to guide the selection of the most promising technologies and their efficient pathway to market approval. Dr. Jeanette Wood, Chairman of Scientific and Drug Discovery [...]